ArticleFEMS microbiology letters2026
A comprehensive report on the 1st Swiss-EUCAST antimicrobial susceptibility testing (AST) meeting.
Article in FEMS microbiology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Antimicrobial susceptibility testing (AST) is being reshaped by increasingly complex resistance mechanisms, revised interpretive frameworks, and rapid phenotypic and genomic technologies. The first Swiss-EUCAST AST Meeting, held in Zurich on 4 May 2026, brought together more than 100 clinical microbiologists, researchers, and infectious diseases specialists to discuss how these developments should be translated into routine diagnostics. The meeting focused on three topics: the limitations of genotype-phenotype prediction, the ongoing need for standardized interpretation within the European Committee on Antimicrobial Susceptibility Testing (EUCAST), and the potential of new technologies to reduce turnaround times. Discussions specifically on Pseudomonas aeruginosa, as well as on pathogens without clinical breakpoints, carbapenemase-producing Enterobacterales, expected phenotypes, epidemiological cutoff values, rapid phenotypic susceptibility tests, and whole-genome sequencing, showed that no single method can eliminate all diagnostic uncertainties. In summary, it was concluded that standardized phenotypic ASTs will continue to serve as a clinical reference in the future, but molecular and genomic methods offer additional advantages in terms of speed, as well as insights into mechanisms of action and epidemiological relations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.